Work

4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results

Year: 2007

Type: article

Study design: Clinical Trial

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(07)71135-7

Authors: B. Escudier, S. Srinivas, J. Roigas, S. Gillessen, U. Harmenberg, P.H. De Mulder, G. Fountzilas, N. Vogelzang, C. Peschel, P. Flodgren

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2000681629

FWCI: 0.894

Cites:

Cited by: 5

Related to: 10